The treatment of tumor cells with Cis-Pt (1 μM) and SLC-0111 (100 μM) as single agents significantly reduced TNBC cell invasiveness (MDA-MB-231 cells: Cis-Pt 58%, SLC-0111 67%; BT-549 cells: Cis-Pt 53%, SLC-0111 62%). This evidence concerns the gene CCL21 and neoplasm.